1692 related articles for article (PubMed ID: 35808868)
21. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
22. Construction and validation of an autophagy-related long noncoding RNA signature for prognosis prediction in kidney renal clear cell carcinoma patients.
Yu J; Mao W; Xu B; Chen M
Cancer Med; 2021 Apr; 10(7):2359-2369. PubMed ID: 33650306
[TBL] [Abstract][Full Text] [Related]
23. Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.
Zhang H; Ning Z; Wang B; Liu Y; Tao B; Zhang G; Liu H; Wang C
Dis Markers; 2023; 2023():7219794. PubMed ID: 36741910
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of necroptosis-related lncRNA signature with potential implications in tumor heterogeneity and prediction of prognosis in clear cell renal cell carcinoma.
Lin H; Qu L; Chen G; Zhang C; Lu L; Chen Y
Eur J Med Res; 2023 Jul; 28(1):236. PubMed ID: 37452355
[TBL] [Abstract][Full Text] [Related]
25. A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma.
Zhang W; Wang H; Wang W; Xue H; Qiao M; Song L; Wang S; Ren Z; Ma Z
Anal Cell Pathol (Amst); 2022; 2022():4673514. PubMed ID: 36588797
[TBL] [Abstract][Full Text] [Related]
26. Analysis of Ferroptosis-Related LncRNAs Signatures Associated with Tumor Immune Infiltration and Experimental Validation in Clear Cell Renal Cell Carcinoma.
Chen X; Tu J; Ma L; Huang Y; Yang C; Yuan X
Int J Gen Med; 2022; 15():3215-3235. PubMed ID: 35342303
[TBL] [Abstract][Full Text] [Related]
27. The necroptosis-related signature and tumor microenvironment immune characteristics associated with clinical prognosis and drug sensitivity analysis in stomach adenocarcinoma.
Yang B; Wang Y; Liu T; Zhang M; Luo T
Aging (Albany NY); 2024 Mar; 16(7):6098-6117. PubMed ID: 38546403
[TBL] [Abstract][Full Text] [Related]
28. An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma.
Tang C; Qu G; Xu Y; Yang G; Wang J; Xiang M
Aging (Albany NY); 2021 Dec; 13(24):26046-26062. PubMed ID: 34954690
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm.
Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y
Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223
[TBL] [Abstract][Full Text] [Related]
30. Selection of M7G-related lncRNAs in kidney renal clear cell carcinoma and their putative diagnostic and prognostic role.
Zhong S; Chen S; Lin H; Luo Y; He J
BMC Urol; 2023 Nov; 23(1):186. PubMed ID: 37968670
[TBL] [Abstract][Full Text] [Related]
31. Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma.
Xu Y; Chen Y; Niu Z; Yang Z; Xing J; Yin X; Guo L; Zhang Q; Yang Y; Han Y
Front Surg; 2022; 9():860806. PubMed ID: 35937602
[TBL] [Abstract][Full Text] [Related]
32. Construction of a ferroptosis-related signature based on seven lncRNAs for prognosis and immune landscape in clear cell renal cell carcinoma.
Wei SY; Feng B; Bi M; Guo HY; Ning SW; Cui R
BMC Med Genomics; 2022 Dec; 15(1):263. PubMed ID: 36528763
[TBL] [Abstract][Full Text] [Related]
33. Identification and validation of a ferroptosis-related lncRNA signature to robustly predict the prognosis, immune microenvironment, and immunotherapy efficiency in patients with clear cell renal cell carcinoma.
Ju L; Shi Y; Liu G
PeerJ; 2022; 10():e14506. PubMed ID: 36570012
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive Analysis of N6-Methylandenosine-Related lncRNAs in Clear Cell Renal Cell Carcinoma: A Correlation With Prognosis, Tumor Progression, and Therapeutic Response.
Meng C; Li J; Wang X; Ying Y; Li Z; Wang A; Li X
Cancer Invest; 2024 Apr; 42(4):278-296. PubMed ID: 38644691
[TBL] [Abstract][Full Text] [Related]
35. Stemness related lncRNAs signature for the prognosis and tumor immune microenvironment of ccRCC patients.
Zhang M; Zhang J; Liang X; Zhang M
BMC Med Genomics; 2024 May; 17(1):150. PubMed ID: 38822402
[TBL] [Abstract][Full Text] [Related]
36. Predicting prognosis, immunotherapy and distinguishing cold and hot tumors in clear cell renal cell carcinoma based on anoikis-related lncRNAs.
Hao C; Li R; Lu Z; He K; Shen J; Wang T; Qiu T
Front Immunol; 2023; 14():1145450. PubMed ID: 37359524
[TBL] [Abstract][Full Text] [Related]
37. The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma.
Zhang L; Di L; Liu J; Lei X; Gu M; Zhang W; Wang Y
Front Genet; 2023; 14():1039813. PubMed ID: 36755568
[TBL] [Abstract][Full Text] [Related]
38. The clinical significance, immune infiltration, and tumor mutational burden of angiogenesis-associated lncRNAs in kidney renal clear cell carcinoma.
Zhang W; Liu Z; Wang J; Geng B; Hou W; Zhao E; Li X
Front Immunol; 2022; 13():934387. PubMed ID: 35958561
[TBL] [Abstract][Full Text] [Related]
39. Immune Infiltration Subtypes Characterization and Identification of Prognosis-Related lncRNAs in Adenocarcinoma of the Esophagogastric Junction.
Hu X; Wu L; Liu B; Chen K
Front Immunol; 2021; 12():651056. PubMed ID: 34122409
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
